Amgen: Phase 3 Study Combining Kyprolis, Darzalex Met Primary Endpoint

Date : 12/10/2019 @ 1:20PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 139.76  0.0 (0.00%) @ 11:19AM
Last Trade
Last $ 142.49 ▲ 2.73 (1.95%)

Amgen: Phase 3 Study Combining Kyprolis, Darzalex Met Primary Endpoint

Historical Stock Chart

6 Months : From Oct 2019 to Apr 2020

Click Here for more Amgen Charts.

By Colin Kellaher


Amgen Inc. (AMGN) on Tuesday said a phase 3 study evaluating Kyprolis in combination with dexamethasone and Darzalex met its primary endpoint in patients with the blood cancer multiple myeloma.

The Thousand Oaks, Calif., biotechnology company said the study met its main endpoint of progression-free survival, resulting in a 37% reduction in the risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

Amgen said the combination also showed efficacy in key secondary endpoints, including overall response rate and overall survival.

Johnson & Johnson's (JNJ) Janssen Biotech Inc. unit has an exclusive license to develop, manufacture and commercialize Darzalex under an August 2012 agreement with Danish biotechology company Genmab A/S (GMAB).


Write to Colin Kellaher at


(END) Dow Jones Newswires

December 10, 2019 08:05 ET (13:05 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.